[1]
|
Siegel, R.L., Miller, K.D., Fuchs, H.E., et al. (2021) Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33. https://doi.org/10.3322/caac.21654
|
[2]
|
何明艳. 乳腺癌流行趋势分析与术后放疗效应研究[D]: [硕士学位论文]. 衡阳: 南华大学, 2019.
|
[3]
|
Yildiz, T., Gu, R., Zauscher, S., et al. (2018) Doxorubicin-Loaded Prote-ase-Activated Near-Infrared Fluorescent Polymeric Nanoparticles for Imaging and Therapy of Cancer. International Journal of Nanomedicine, 13, 6961-6986.
https://doi.org/10.2147/IJN.S174068
|
[4]
|
Harbeck, N., Penault-Llorca, F., Cortes, J., et al. (2019) Breast Cancer. Nature Reviews Disease Primers, 5, Article No. 66. https://doi.org/10.1038/s41572-019-0111-2
|
[5]
|
Conforti, F., Pala, L., Sala, I., et al. (2021) Evaluation of Pathological Complete Response as Surrogate Endpoint in Neoadjuvant Randomised Clinical Trials of Early Stage Breast Cancer: Systematic Review and Meta-Analysis. BMJ, 375, e066381. https://doi.org/10.1136/bmj-2021-066381
|
[6]
|
Fisher, B., Brown, A., Mamounas, E., et al. (1997) Effect of Pre-operative Chemotherapy on Local-Regional Disease in Women with Operable Breast Cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. Journal of Clinical Oncology, 15, 2483-2493. https://doi.org/10.1200/JCO.1997.15.7.2483
|
[7]
|
Rastogi, P., Anderson, S.J., Bear, H.D., et al. (2008) Preopera-tive Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. Journal of Clinical Oncology, 26, 778-785.
https://doi.org/10.1200/JCO.2007.15.0235
|
[8]
|
Loibl, S. (2015) Neoadjuvant Treatment of Breast Cancer: Max-imizing Pathologic Complete Response Rates to Improve Prognosis. Current Opinion in Obstetrics and Gynecology, 27, 85-91.
https://doi.org/10.1097/GCO.0000000000000147
|
[9]
|
芦洁. 影响乳腺癌新辅助化疗疗效及预后的相关因素分析[D]: [硕士学位论文]. 乌鲁木齐: 新疆医科大学, 2019.
|
[10]
|
张小飞, 覃庆洪, 练斌, 等. 167例Ⅱ、Ⅲ期乳腺癌新辅助化疗疗效评价及影响因素[J]. 现代肿瘤医学, 2015, 23(13): 1823-1827.
|
[11]
|
Jin, X., Jiang, Y.Z., Chen, S., et al. (2016) A Nomogram for Predicting Pathological Complete Response in Patients with Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer. BMC Cancer, 16, Article No. 606.
https://doi.org/10.1186/s12885-016-2652-z
|
[12]
|
Goorts, B., Van Nijnatten, T.J., De Munck, L., et al. (2017) Clinical Tumor Stage Is the Most Important Predictor of Pathological Complete Response Rate after Neoadjuvant Chemotherapy in Breast Cancer Patients. Breast Cancer Research and Treatment, 163, 83-91. https://doi.org/10.1007/s10549-017-4155-2
|
[13]
|
Xu, Y., Chen, M., Liu, C., et al. (2017) Association Study Con-firmed Three Breast Cancer-Specific Molecular Subtype-Associated Susceptibility Loci in Chinese Han Women. On-cologist, 22, 890-894.
https://doi.org/10.1634/theoncologist.2016-0423
|
[14]
|
Mei, F., Liu, J.Y. and Xue, W.C. (2019) [Histological Grading of Invasive Breast Carcinoma: Nottingham Histological Grading System]. Chinese Journal of Pathology, 48, 659-664.
|
[15]
|
蔡媛, 翁寿田, 车潇良, 等. 乳腺癌组织学类型及分级对预测新辅助化疗疗效的价值[J]. 现代肿瘤医学, 2013, 21(1): 78-80.
|
[16]
|
Tewari, M., Krishnamurthy, A. and Shukla, H.S. (2008) Predictive Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer. Surgical Oncology, 17, 301-311. https://doi.org/10.1016/j.suronc.2008.03.003
|
[17]
|
Miyoshi, Y., Kurosumi, M., Kurebayashi, J., et al. (2008) Low Nuclear Grade But Not Cell Proliferation Predictive of Pathological Complete Response to Docetaxel in Human Breast Cancers. Journal of Cancer Research and Clinical Oncology, 134, 561-567. https://doi.org/10.1007/s00432-007-0319-5
|
[18]
|
覃舒婷, 莫军扬, 周韬. 乳腺癌分子亚型对新辅助化疗疗效及预后的预测价值[J]. 实用医学杂志, 2015, 31(6): 953-955.
|
[19]
|
王勒, 郑红梅, 吴新红, 等. 乳腺癌临床病理特征和分子分型对新辅助化疗疗效及预后的预测价值[J]. 中华实用诊断与治疗杂志, 2019, 33(8): 739-743.
|
[20]
|
Haque, W., Verma, V., Hatch, S., et al. (2018) Response Rates and Pathologic Complete Response by Breast Cancer Molecular Subtype Following Neoadjuvant Chemotherapy. Breast Cancer Research and Treatment, 170, 559-567.
https://doi.org/10.1007/s10549-018-4801-3
|
[21]
|
Ohara, A.M., Naoi, Y., Shimazu, K., et al. (2019) PAM50 for Prediction of Response to Neoadjuvant Chemotherapy for ER-Positive Breast Cancer. Breast Cancer Research and Treatment, 173, 533-543.
https://doi.org/10.1007/s10549-018-5020-7
|
[22]
|
Lashen, A.G., Toss, M.S., Ghannam, S.F., et al. (2023) Expres-sion, Assessment and Significance of Ki67 Expression in Breast Cancer: An Update. Journal of Clinical Pathology, 76, 357-364. https://doi.org/10.1136/jcp-2022-208731
|
[23]
|
Finkelman, B.S., Zhang, H., Hicks, D.G., et al. (2023) The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations. Cancers, 15, Article 808.
https://doi.org/10.3390/cancers15030808
|
[24]
|
刘现义, 王晓春, 张丹丹, 等. LRP16、Ki67及EGFR表达与乳腺癌的临床病理因素及预后的关系探讨[J]. 中国地方病防治杂志, 2017, 32(4): 456, 458.
|
[25]
|
Chen, X., He, C., Han, D., et al. (2017) The Predictive Value of Ki-67 before Neoadjuvant Chemotherapy for Breast Cancer: A Systematic Review and Meta-A2017nalysis. Future Oncology, 13, 843-857.
https://doi.org/10.2217/fon-2016-0420
|
[26]
|
Chen, R., Ye, Y., Yang, C., et al. (2018) Assessment of the Predictive Role of Pretreatment Ki-67 and Ki-67 Changes in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy according to the Molecular Classification: A Retrospective Study of 1010 Patients. Breast Cancer Research and Treatment, 170, 35-43.
https://doi.org/10.1007/s10549-018-4730-1
|
[27]
|
Ricciardi, G.R., Adamo, B., Ieni, A., et al. (2015) Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients. PLOS ONE, 10, e0128368.
https://doi.org/10.1371/journal.pone.0128368
|
[28]
|
梁晨露, 王晨, 俞星飞, 等. 三阴性乳腺癌新辅助化疗后Ki67表达变化与患者生存的关系[J]. 中华乳腺病杂志(电子版), 2019, 13(3): 145-149.
|
[29]
|
Iyengar, N.M., Gucalp, A., Dannenberg, A.J., et al. (2016) Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation. Journal of Clinical Oncology, 34, 4270-4276. https://doi.org/10.1200/JCO.2016.67.4283
|
[30]
|
Cui, D., Huang, Z., Liu, Y. and Ouyang, G.L. (2017) The Multifaceted Role of Periostin in Priming the Tumor Microenvironments for Tumor Progression. Cellular and Molecular Life Sciences, 74, 4287-4291.
https://doi.org/10.1007/s00018-017-2646-2
|
[31]
|
Sivapiragasam, A., Ashok Kumar, P., Sokol, E.S., et al. (2021) Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer. Cancer Medicine, 10, 53-61. https://doi.org/10.1002/cam4.3550
|
[32]
|
Kaewkangsadan, V., Verma, C., Eremin, J.M., et al. (2016) Crucial Con-tributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to A Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer. Journal of Immunology Research, 2016, Article ID: 4757405. https://doi.org/10.1155/2016/4757405
|
[33]
|
Ingold Heppner, B., Untch, M., Denkert, C., et al. (2016) Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. Clinical Cancer Research, 22, 5747-5754.
https://doi.org/10.1158/1078-0432.CCR-15-2338
|
[34]
|
Nestor, C.E., Ottaviano, R., Reinhardt, D., et al. (2015) Rapid Reprogramming of Epigenetic and Transcriptional Profiles in Mammalian Culture Systems. Genome Biology, 16, Article No. 11. https://doi.org/10.1186/s13059-014-0576-y
|
[35]
|
Sigin, V.O., Kalinkin, A.I., Nikolaeva, A.F., et al. (2023) DNA Methylation and Prospects for Predicting the Therapeutic Effect of Neoadjuvant Chemotherapy for Tri-ple-Negative and Luminal B Breast Cancer. Cancers, 15, Article 1630. https://doi.org/10.3390/cancers15051630
|
[36]
|
Pedersen, C.A., Cao, M.D., Fleischer, T., et al. (2022) DNA Meth-ylation Changes in Response to Neoadjuvant Chemotherapy Are Associated with Breast Cancer Survival. Breast Cancer Research, 24, Article No. 43.
https://doi.org/10.1186/s13058-022-01537-9
|
[37]
|
Hsu, P.C., Kadlubar, S.A., Siegel, E.R., et al. (2020) Ge-nome-Wide DNA Methylation Signatures to Predict Pathologic Complete Response from Combined Neoadjuvant Chemotherapy with Bevacizumab in Breast Cancer. PLOS ONE, 15, e0230248. https://doi.org/10.1371/journal.pone.0230248
|
[38]
|
Meyer, B., Clifton, S., Locke, W., et al. (2021) Identification of DNA Methylation Biomarkers with Potential to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Clinical Epigenetics, 13, Article No. 226. https://doi.org/10.1186/s13148-021-01210-6
|
[39]
|
Wang, H., Guo, M., Wei, H., et al. (2023) Targeting P53 Pathways: Mechanisms, Structures, and Advances in Therapy. Signal Transduction and Targeted Therapy, 8, Article No. 92. https://doi.org/10.1038/s41392-023-01347-1
|
[40]
|
Levine, A.J. (2020) P53: 800 Million Years of Evolution and 40 Years of Discovery. Nature Reviews Cancer, 20, 471-480. https://doi.org/10.1038/s41568-020-0262-1
|
[41]
|
Sullivan, K.D., Galbraith, M.D., Andrysik, Z. and Espinosa, J.M. (2018) Mechanisms of Transcriptional Regulation by P53. Cell Death & Differentiation, 25, 133-143. https://doi.org/10.1038/cdd.2017.174
|
[42]
|
Darb-Esfahani, S., Denkert, C., Stenzinger, A., et al. (2016) Role of TP53 Mutations in Triple Negative and HER2-Positive Breast Cancer Treated with Neoadjuvant Anthracycline/Taxane-Based Chemotherapy. Oncotarget, 7, 67686-67698. https://doi.org/10.18632/oncotarget.11891
|
[43]
|
Albinsaad, L.S., Kim, J., Chung, I.Y., et al. (2021) Prognostic Value of P53 Expression in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Breast Cancer Research and Treatment, 187, 447-454. https://doi.org/10.1007/s10549-021-06134-6
|
[44]
|
Burgess, A.W., Cho, H.S., Eigenbrot, C., et al. (2003) An Open-And-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors. Molecular Cell, 12, 541-552. https://doi.org/10.1016/S1097-2765(03)00350-2
|
[45]
|
Mendelsohn, J. (2002) Targeting the Epidermal Growth Factor Receptor for Cancer Therapy. Journal of Clinical Oncology, 20, 1s-13s.
|
[46]
|
Radosevic-Robin, N., Selenica, P., Zhu, Y., et al. (2021) Recurrence Biomarkers of Triple Negative Breast Cancer Treated with Neoadjuvant Chemotherapy and Anti-EGFR Antibodies. NPJ Breast Cancer, 7, Article No. 124.
https://doi.org/10.1038/s41523-021-00334-5
|
[47]
|
石国建, 顾蓓, 郭斌, 等. 局部晚期乳腺癌患者新辅助化疗前后P53、Ki-67、NM23、EGFR的表达变化及临床意义[J]. 癌症进展, 2019, 17(7): 812-816.
|
[48]
|
魏朋. 乳腺癌组织中PD-1、PD-L1的表达与新辅助化疗疗效的相关性[J]. 航空航天医学杂志, 2022, 33(8): 947-950.
|
[49]
|
Shang, M., Chi, Y., Zhang, J., et al. (2022) The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression. Frontiers in Oncology, 11, Article 706606. https://doi.org/10.3389/fonc.2021.706606
|
[50]
|
徐海敏, 戴瑶, 马雨竹, 等. MRT1WI瘤体及瘤周影像组学联合临床特征预测乳腺癌新辅助化疗疗效[J]. 中国医学影像技术, 2023, 39(10): 1520-1525.
|